skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: November 2020 was your last response on the business fundamentals of this company. Recognizing that the stock price has dropped even more since then, what has changed with this company's outlook when comparing time periods?

How is its balance sheet and drug pipeline compared to Pfizer?

Pfizer is clearly more of an income play but that aside, do you favour one or the other for any particular reason?
Read Answer Asked by James on February 25, 2025
Q: ALT: US What is your impression on this clinical stage bio pharmaceutical company ?
Do these small bio pharma companies have any chance of being a take out target from the larger player?
What is your risk assessment on this company
From 1-10 . 1 being high risk . 10 being low risk.

Thanks
Cal .
Read Answer Asked by cal on February 21, 2025
Q: It looks like biotech stocks are on a tear, especially those that may benefit from AI. Do you have any names that you might recommend? I'm considering the Arkg fund but I don't quite trust Cathy Woods after losing money on the Arkk fund in 2021. Thank you,

Jason
Read Answer Asked by Jason on February 18, 2025
Q: Hello,

Given the current price levels of both MRNA and PFE would this be a good time to take position in either one of those? If so which one would you recommend.

Thank you!
Read Answer Asked by Irek on February 14, 2025
Q: Thank you for your prompt answer; I was not sure whether the company consistently advised much lower prospects or whether there was some seasonality to their earnings. My take is that corporate earnings prospects do need to be as accurate as possible and is an appropriate response, and guidance, to shareholders investment.
Read Answer Asked by Mike on February 12, 2025